Lupin Limited and DKSH announced that they have signed an exclusive license and supply agreement to commercialize five of Alvotech's proposed biosimilars in the Philippines. The biosimilars planned under this agreement include biosimilar Prolia® (denosumab 60mg/ml), Xgeva® (denosumab 70 mg/ml), Simponi® (golimumab), and Eylea® (aflibercept) as well as two undisclosed proposed biosimilars for immunology and oncology.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.4 USD | -0.76% | +1.77% | +25.44% |
Apr. 30 | Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals | MT |
Apr. 30 | Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,655 INR | +0.46% | +2.44% | 9.05B | ||
60.5 CHF | +0.83% | +1.51% | 4.34B | ||
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+25.44% | 4.03B | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- ALVO Stock
- News Alvotech
- Lupin Limited and DKSH Sign an Exclusive License and Supply Agreement with Alvotech